Virginia Governor Northam Announces Industrial Hemp Company to Locate In Rockingham County

Governor Northam Announces Industrial Hemp Company to Locate in Rockingham County

VIRGINIA:  Governor Ralph Northam today announced that Shenandoah Valley Hemp, LLC dba Pure Shenandoah will invest nearly $3.3 million to establish an industrial hemp fiber processing and cannabidiol (CBD) oil extraction facility in the historic Casey Jones building in the Town of Elkton. The company will create 24 new jobs and has committed to purchasing 100 percent of its industrial hemp from Virginia growers, resulting in nearly $5 million in payments to Virginia farmers over the next three years. Pure Shenandoah will become the first participant in the Virginia’s Finest trademark program to source the hemp used in its products exclusively from the Commonwealth.

“Virginia’s industrial hemp industry continues to experience tremendous growth, creating a wealth of opportunity across our Commonwealth,” said Governor Northam. “Projects like this one are an important part of diversifying our economy and developing new markets for industrial hemp. Our administration remains committed to supporting growers and processors as we work to ensure this crop has a sustainable future in Virginia.”

Pure Shenandoah operates as a vertically integrated “seed to sale” company providing customers with safe and consistent hemp products of the highest quality. This includes strict regulatory control of crops, the application of certified good manufacturing practices, and complete traceability of each product back to the seed and farm from which it came.

“Pure Shenandoah is a great example of the many ways we are able to help innovative, agriculture-based companies grow and thrive in the Commonwealth,” said Secretary of Agriculture and Forestry Bettina Ring. “I am pleased to see continued job creation and investment in Virginia’s industrial hemp industry and excited for the new market opportunities the industry is creating for our farmers.”

“Industrial hemp is gaining momentum across the country, and we are excited for Virginia to be a player in this up-and-coming industry,” said Secretary of Commerce and Trade Brian Ball. “Pure Shenandoah will provide quality jobs and enable the Commonwealth’s hemp growers to source extraction and processing within Virginia, further benefiting our economy and agricultural ecosystem.”

As part of its strategic marketing efforts, Pure Shenandoah is a participating member of the Virginia’s Finest® program. Created more than 30 years ago with more than 500 participating companies, this program helps consumers know they are purchasing top-quality Virginia-produced specialty food products whenever they see the classic blue and red VA check mark logo.

“We are honored to receive these funds and to work with such influential state programs that are helping push the industrial hemp industry forward in the Commonwealth,” said Pure Shenandoah CEO Tanner Johnson. “With this support, we will continue to educate and provide safe and effective products to consumers. We are excited to do our part and help expand the future of industrial hemp and all of its potential.”

The Virginia Department of Agriculture and Consumer Services (VDACS) and Virginia Economic Development Partnership (VEDP) worked with Rockingham County and the Rockingham County Economic Development Authority to secure this project for the Commonwealth. Governor Northam approved a $50,000 grant from the Governor’s Agriculture and Forestry Industries Development (AFID) Fund for the project, which Rockingham County will match with local funds. Funding and services to support the company’s job creation will be provided through VEDP’s Virginia Jobs Investment Program.

“Rockingham County is pleased with the announcement of 24 new jobs and the investment of $3.3 million in eastern Rockingham County,” said Chairman of the Rockingham County Board of Supervisors Bill Kyger. “This is a new and exciting industry that offers a great opportunity to diversify the agriculture base of the county for the future.”

“We should never forget or take for granted Virginia’s tremendous agricultural heritage and its economic viability that continues to push Virginia forward,” said Senator Emmett Hanger. “I am pleased the AFID funds will further promote industrial hemp and that Pure Shenandoah is committed to exclusively sourcing Virginia agriculture products for this project. Of course, there is no better county to partner with on this funding than the number one agricultural county in the Commonwealth, Rockingham County. We are proud of our deep agricultural roots here in Virginia and this economic announcement adds yet another facet to our diverse agriculture operations.”

FDA Warns Companies Illegally Selling CBD Products

DISTRICT OF COLUMBIA:  The U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). All five warning letters address the illegal marketing of unapproved CBD products claiming to treat medical conditions. The warning letters include CBD products that are especially concerning from a public health perspective due to the route of administration, including nasal, ophthalmic and inhalation. In addition, they address violations relating to the addition of CBD to food, and the impermissible marketing of CBD products as dietary supplements. Two of the letters also address CBD products illegally marketed for pets, including a product for use in the eye.

“The FDA’s first priority is to protect the health and safety of Americans. Many questions remain regarding the science, safety, effectiveness and quality of products containing CBD,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “We remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety. Meanwhile, we will continue to monitor and take action, as needed, against companies that unlawfully market their products — prioritizing those that pose the greatest risk of harm to the public.”

The warning letters were issued to:

The FDA has previously sent warning letters to other companies illegally selling unapproved CBD products that claimed to prevent, diagnose, mitigate, treat or cure various diseases, in violation of the FD&C Act. In some cases, there were further violations because CBD was added to food, and some of the products were impermissibly marketed as “dietary supplements.”

The products that are the subject of the letters issued today have not gone through the FDA drug approval process and therefore are considered unapproved new drugs. It is not known whether they are effective for the uses claimed in labeling, what an appropriate dose might be, how they could interact with FDA-approved drugs or other products or whether they have dangerous side effects or other safety concerns. In addition, the manufacturing process of these unapproved CBD-containing drug products has not been subject to FDA review as part of the human or animal drug approval processes, so it is not known what the manufacturing conditions of, or contaminant levels in these products may be.

Under the FD&C Act, any product intended to diagnose, cure, mitigate, treat or prevent a disease, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. New human and animal drugs must be approved by the FDA or conform to a “monograph” for a particular drug category, as established by FDA’s Over-the-Counter (OTC) Drug Review, before they can be legally marketed as drugs. CBD was not an ingredient considered under the OTC Drug Review.

The FDA has not approved any CBD products other than one prescription drug for the treatment of seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in human patients. CBD has not been approved as a food additive and does not meet the statutory definition of a dietary supplement.

The FDA has requested responses from the companies within 15 working days stating how they will address these issues, or providing their reasoning and supporting information as to why they think the products are not in violation of the law. Failure to adequately address the violations promptly may result in legal action, including product seizure and/or injunction.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

FTC Announces Crackdown On Deceptively Marketed CBD Products

Companies made unsupported claims that their oils, balms, gummies, coffee, and other goods could treat serious diseases such as cancer and diabetes

DISTRICT OF COLUMBIA: The Federal Trade Commission today announced the first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The FTC is taking action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others.

The FTC is requiring each of the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency. The orders settling the FTC’s complaints also bar the respondents from similar deceptive advertising in the future, and require that they have scientific evidence to support any health claims they make for CBD and other products.

“The six settlements announced today send a clear message to the burgeoning CBD industry: Don’t make spurious health claims that are unsupported by medical science,” said Andrew Smith, Director of the FTC’s Bureau of Consumer Protection. “Otherwise, don’t be surprised if you hear from the FTC.”

The crackdown, Operation CBDeceit, is part of the Commission’s ongoing effort to protect consumers from false, deceptive, and misleading health claims made in advertisements on websites and through social media companies such as Twitter.

Each case the FTC is announcing today is described below:

Bionatrol Health, LLC

According to the FTC’s complaint against Utah-based companies Bionatrol Health, LLC and Isle Revive, LLC, and two former managers and owners, since at least December 2019 the respondents sold a CBD oil to consumers on two websites. Among other things, the respondents allegedly claimed without substantiation that their CBD product is safe for all users, treats pain better than prescription medications like OxyContin, and prevents and treats age-related cognitive decline and chronic pain. The respondents also claimed, without scientific evidence, that CBD oil is “medically proven” to improve a variety of conditions, according to the FTC’s complaint. In addition, the FTC alleges the respondents deceived consumers who ordered one bottle of their CBD oil by changing the order to five bottles without consumers’ consent.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs without human clinical testing to substantiate the claims. It also requires competent and reliable scientific evidence for other health-related product claims, and prohibits the respondents from misrepresenting the cost of any good or service and from charging consumers without their express, informed consent. Finally, it requires the corporate respondents and individual respondent Marcello Torre to pay $20,000 to the FTC and to notify consumers of the Commission’s order.

Epichouse LLC (First Class Herbalist CBD)

According to the FTC’s complaint against Utah corporation Epichouse, LLC, which operated under several names, including First Class Herbalist, and the company’s founder and owner, John Le, since at least September 2019 the respondents sold several CBD products on their website, including oils, a pain-relief cream, coffee, and gummies.

Among other alleged unsupported claims, Epichouse and Le promoted CBD as safe for all users, able to treat pain better than prescription medications such as OxyContin, and able to prevent a wide range of serious conditions, including cancer, diabetes, and heart disease. In their advertising, they also falsely claimed that CBD is scientifically proven to improve many serious health conditions—including chronic pain and hypertension—and provide neurological benefit—such as preventing age-related cognitive decline—according to the FTC’s complaint.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, the order requires the respondents to pay $30,000 to the FTC and notify consumers of the Commission’s order.

CBD Meds, Inc.

According to the FTC’s complaint against CBD Meds, Inc.; G2 Hemp, Inc.; and Lawrence Moses, a/k/a Lawrence D. Moses, Jr., individually and as an officer of the corporate entities, the two companies advertised CBD oil on their website and on YouTube. In their ads, the FTC contends, the Winchester, California-based firms made a number of false or unsubstantiated claims, including that CBD effectively treats, prevents, or mitigates serious diseases and conditions like artery blockage, cancer, glaucoma, autism, and schizophrenia, among many others. The respondents also falsely represented that some of the efficacy claims were scientifically proven or that the U.S. government has confirmed the health benefits of CBD.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, the order requires the respondents to notify consumers of the Commission’s order.

HempmeCBD

According to the FTC’s complaint against EasyButter, LLC, also d/b/a HempmeCBD, and its owner and officer Michael Solomon, since at least January 2018, the respondents have sold CBD products on their website, including CBD-infused shea butter, gummies, lozenges, honey sticks, vape pens, and oils. The complaint alleges that HempmeCBD claimed its CBD products could treat or cure serious ailments like cancer-related symptoms, substance abuse, and AIDS. The complaint alleges HempmeCBD lacked the scientific substantiation for such health claims and falsely claimed to have studies showing CBD is effective at treating autism.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It also requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires the respondents to pay the FTC $36,254 and to notify consumers of the Commission’s order.

Reef Industries, Inc.

According to the FTC’s complaint against California-based Reef Industries, Inc.; Cannatera, Inc.; AndHemp, Ltd., and the companies’ three principals, the respondents have sold a variety of CBD products directly to consumers on their website and Twitter accounts since at least January 2019 and misrepresented the health benefits of CBD. The FTC alleges that the respondents made unsubstantiated claims that CBD can prevent, cure, mitigate, or treat diseases and serious health conditions, including Alzheimer’s disease, arthritis, autoimmune disease, and irritable bowel syndrome. The complaint also alleges the respondents falsely claimed that studies or scientific research prove that CBD is effective at treating, curing, or mitigating these diseases and conditions.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires them to pay the FTC $85,000 and notify consumers of the Commission’s order.

Steves Distributing, LLC

According to the FTC’s complaint against Steves Distributing, LLC, d/b/a Steve’s Goods; and the company’s CEO Steven Taylor Schultheis, since beginning operations in 2018, the respondents have sold a variety of products containing both CBD and cannabigerol (CBG), which, like CBD, is a non-psychoactive compound derived from hemp. The company advertises its CBD and CBG products, including tinctures, gummies, capsules, topical balms, suppositories, bath balms, and coffee, on its website and through social media companies like Twitter.

The FTC alleges that the respondents claimed, without adequate substantiation, that their CBD and CBG products are effective alternatives to prescription medications and treat a wide range of diseases and serious health conditions, including Alzheimer’s disease, cancer, and diabetes. The complaint also alleges the respondents falsely claimed that their CBD and CBG products have antibacterial properties, prevent or reduce the risk of heart attacks, strokes, and other diseases, and that certain of these claims were supported by scientific evidence.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires the respondents to pay the FTC $75,000 and notify consumers of the Commission’s order.

The Commission votes approving each of the six administrative complaints and proposed consent orders were 5-0, with Commissioner Rohit Chopra and Commissioner Christine S. Wilson issuing separate, concurring statements. A complete list of respondents can be found in the complaint for each respective case.

The FTC will publish a description of the consent agreement package in the Federal Register soon. The agreement will be subject to public comment for 30 days after publication in the Federal Register after which the Commission will decide whether to make the proposed consent order final. Instructions for filing comments will appear in the published notice. Once processed, comments will be posted on Regulations.gov.

NOTE: The Commission issues an administrative complaint when it has “reason to believe” that the law has been or is being violated, and it appears to the Commission that a proceeding is in the public interest. When the Commission issues a consent order on a final basis, it carries the force of law with respect to future actions. Each violation of such an order may result in a civil penalty of up to $43,280.

Dr. Rand Paul Introduces HEMP Act To Relieve Unnecessary Constraints On Hemp Industry, Provide Transparency And Certainty

DISTRICT OF COLUMBIA: U.S. Senator Rand Paul (R-KY) continued his efforts to address Kentucky hemp farmers’ concerns with federal overreach and bring clarity, transparency, and certainty to regulation by introducing the Hemp Economic Mobilization Plan (HEMP) Act of 2020.

In response to concerns raised by Kentucky hemp farmers and processors, Dr. Paul’s HEMP Act would change the legal definition of hemp to raise the THC limit from 0.3% to 1%. Currently, any hemp crops testing above 0.3% have to be destroyed.

The legislation would require testing of the final hemp-derived product instead of the hemp flower or plant itself, as the 15-day window for testing the hemp flower or plant does not take potential testing backlogs, lack of personnel to collect samples, harvesting time, or environmental factors that farmers cannot control into account.

Dr. Paul’s HEMP Act would also protect legitimate hemp farmers, processors, and transporters by requiring hemp shipments to contain a copy of the seed certificate showing the hemp was grown from 1% THC seed, and it would address current uncertainty by defining a margin of error for testing THC levels. Neither current law nor the USDA’s interim final rule provide such a margin.

“For years, I’ve led the fight in Washington to restore one of Kentucky’s most historically vital crops by legalizing industrial hemp. We achieved a hard-won victory, but there is still work to do to prevent the federal government from weighing down our farmers with unnecessary bureaucratic micromanaging. My legislation will help this growing industry reach its full economic potential, and I am proud the bill has strong support all the way from local Kentucky farmers and activists to national groups, including the American Farm Bureau Federation,” said Dr. Paul.

“The U.S. hemp industry has had its share of roadblocks, but we continue to push forward and make changes that will help hemp producers thrive. Senator Paul’s HEMP Act has the potential to improve upon the highest priority issues for hemp growers, processors, and labs, while making sure to keep our consumers safe as well. We are grateful for the continued support from our federal delegation and ask that folks at home call their Congressional representatives to ask for their support,” said Katie Moyer, Owner of Kentucky Hemp Works. 

“We are so excited to hear about Senator Paul’s H.E.M.P. Act, which will help farmers, processors and retailers in our young hemp industry. We believe that loosening up some important interstate business requirements are a much-needed step toward more prosperous times in the hemp economy,” said Kentucky Hemp Association President Tate Hall and Vice President Jana Groda. 

“We appreciate Sen. Paul’s leadership and support for hemp farmers in Kentucky and across the United States. The HEMP Act makes critical improvements that will better allow farmers to successfully grow and profit from hemp,” said Vote Hemp President Eric Steenstra.

Dr. Paul has been a leading voice for removing government restrictions on hemp, and his past efforts, including championing legislation, testifying before the Kentucky legislature, and advocating for Kentucky farmers in Washington, have helped ensure Kentucky can rebuild its hemp industry and push forward to a prosperous future. You can find a video detailing his efforts HERE.

You can read Dr. Paul’s HEMP Act of 2020 HERE, and you can find background and further details in a one-pager HERE.

Hemp Producers In Delaware Must Register Growing Sites Annually

DELAWARE:  The Delaware Department of Agriculture (DDA) is reminding hemp producers to register their growing sites using the annual Growing Site Registration form to register available online before February 1.

Also, any individual who intends to grow, cultivate or distribute hemp, including transplants, seedlings, or clones, must apply to be a Delaware Domestic Hemp Production Program Producer, with renewal required every three years. As described in the Delaware Domestic Hemp Production Program Participant Guide online at https://de.gov/hemp, there are also requirements for processors and handlers.

Under the Delaware Domestic Hemp Production Program, the Delaware Department of Agriculture is responsible for regulating hemp production. The Department does not have oversight of the selling of hemp products or the businesses marketing these products, including any CBD product.

In 2020, Delaware had 13 registered producers with 75 acres registered for outdoor production and 34,000 square feet of indoor production space.

As producers begin the process of applying for the first time or renewing their growing sites for 2021, DDA issued the following reminders:

  • When purchasing seed, all seed is still subject to the Federal Seed Act and Delaware Seed Law, which regulate seed tags and labeling.
  • Producers can designate one person as an Authorized Representative with authority to be present at sample collection and correspond with the Department. This person must be indicated on the Producer Application and must submit a Criminal History Report.
  • The Department requires only one Criminal History Report if applying for more than one license type. Criminal History Reports are to be submitted at the time of application or renewal and must be dated no more than four months prior.

The 2021 Delaware Domestic Hemp Production Program is fee-based as outlined in the Participant Guide and applications found online at https://de.gov/hemp. Producers, processors, and handlers who have questions about Delaware’s Domestic Hemp Production Program should email DDA_HempProgram@delaware.gov.

Hemp, Inc. Settles Longstanding Lawsuit With Securities And Exchange Commission

NEVADA:  Hemp, Inc. announced that it has settled the longstanding 5-year old SEC civil case. Hemp, Inc. and Bruce Perlowin have agreed to settle the civil suit against them without admitting or denying the SEC’s allegations. Perlowin is transitioning from CEO to Chief Visionary Consultant (CVC) and will not be managing the day-to-day tasks of the company. He will, however, remain as the true visionary Hemp, Inc. shareholders have come to admire and respect.

The Company remains committed to its longstanding goals and will be aggressively moving forward to add new blood and new ideas to the management of the company. In the first quarter 2021, Hemp, Inc. will expand its knowledge base by bringing in a new CEO and new members of its Board of Directors.

Minnesota: Congressman Peterson Joins Smith, Craig and McCollum To Urge Federal Agencies To Clarify Hemp Rules

MINNESOTA: Representative Collin Peterson today jointed U.S. Senator Tina Smith (D-Minn.) and U.S. Representatives Angie Craig (D-MN 2), and Betty McCollum (D-MN 4) in calling on the leaders of four federal agencies to streamline hemp rules. Currently, contradictory federal guidelines are leading to uncertainty in the market and preventing Minnesota farmers and Tribes from fully reaping the economic benefits of growing hemp.

“The bipartisan 2018 Farm Bill legalized hemp in order to create economic opportunities for farmers. Minnesota farmers appreciate the United States Department of Agriculture’s (USDA) efforts in implementing the Interim Rule on Establishment of a Domestic Hemp Production Program. However, despite the Interim Rule there are still hurdles in place for Minnesota farmers to fully realize the economic benefits of growing hemp,” wrote the lawmakers in their letter to the United States Department of Agriculture (USDA), the Office of Management and Budget (OMB), the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Sen. Smith and Reps. Craig, McCollum and Peterson go on to identify some of the inconsistencies that need to be addressed: “The federal regulatory framework has proven to be inconsistent. For example, the USDA’s rule stated that farmers will be held accountable – facing possible revoking of their licenses – if their crops test above a .5 percent THC level three times in a five year period. Despite this somewhat onerous and arbitrary level, the Drug Enforcement Agency (DEA) instituted their own rule saying that exceeding .3 percent THC level deems the crop a controlled substance.

The burdensome competing rules don’t allow for remediation if the crop tests above the deemed inappropriate levels. Farmers should not be penalized for plants that they intended to grow as hemp, but for any number of reasons, the final THC numbers exceeded the arbitrary 0.3% THC level.  At the same time, the Food and Drug Administration (FDA) guidance on CBD is still pending at the Office of Management and Budget (OMB), which adds even more uncertainty to the marketplace.”

NIHC Receives USDA MAP Funding for International Research And Promotion Of Hemp

DISTRICT OF COLUMBIA: National Industrial Hemp Council today announced it received $200,000 in U.S. Department of Agricultural (USDA) Market Access Program (MAP) funding to support export market development of industrial hemp.

“We are grateful for USDA confidence and the recognition of NIHC as the industry leader in industrial hemp trade and marketing,” said Kevin Latner, NIHC’s Senior Vice President for Trade and Marketing who will be responsible for implementing the program.  “Today’s announcement makes NIHC a trusted partner to USDA for hemp fiber, feed, food and CBD companies looking to break down trade barriers in markets overseas.”

MAP funds are administered through USDA’s Foreign Agricultural Service (FAS). Through the MAP program, FAS partners with U.S. agricultural trade associations, cooperatives, state regional trade groups and small businesses to share the costs of overseas marketing and promotional activities that help build commercial export markets for U.S. agricultural products and commodities. These funds can be used for facilitating trade missions and meeting with industry stakeholders and government regulators overseas.

NIHC programs will focus on Europe and China and include market research, trade policy and trade facilitation.  The global industrial hemp and products market was estimated at $11.1 billion in retail sales in 2019.  With an annual growth rate of 52 percent, driven by continued strength in textiles, food and industrial uses and hemp-derived cannabidiol (CBD), the global market is forecast to be worth $89 billion by 2025.

Hemp for industrial use, textile and CBD market is expected to quickly expand and be the primary driver of global industry growth.  By 2021, the global trade of hemp is forecast $8.1 billion across all markets, representing a three-year compound annual growth rate (CAGR) of 83 percent.  EuropeChina, and Canada are currently the primary sources of industrial hemp.  With the passage of the 2018 Farm Bill, the U.S. has become the world’s third largest producer of industrial hemp.

Europe has rapidly developed a robust hemp and CBD market.  Europe is also a strong producer of industrial use hemp products with $424 million in industrial product sales. China has led global markets in textiles with almost 80 percent of the $1.7 billion hemp textile market, in 2019.

In addition, National Industrial Hemp Council members will now have unprecedented access to United States trade negotiators; foreign government counterparts; and a network of international hemp industry association counterparts. Foreign governments understand that NIHC is now supported by the U.S. government and represents U.S. industry interests.

Market Access Program funds can be used by NIHC throughout the world to support market access and trade policy work, international trade promotion including supporting business-to-business facilitation, and consumer and brand marketing.

MAP funds for 2021 will be administered to NIHC through the Food Export Association of the Midwest USA.    

“We’re extremely confident and trust that NIHC will represent the best interests of U.S. industrial hemp abroad. We’re excited to be working with them as part of the USDA cooperator community,” said Tim Hamilton, Executive Director of Food Export Association of the Midwest USA.

Canopy Growth Expands Beverage Portfolio with Launch of First CBD-Infused Beverage Line Quatreau

New Product Line Features A Range of Naturally Flavoured Cannabis-Infused Sparkling Waters In Both CBD-only and Balanced (CBD + THC) Offerings

CANADA: Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, today announced the launch of Quatreau, a new line of premium CBD-infused beverages. The naturally flavoured sparkling waters are Canopy Growth’s first CBD-infused drinks, with both CBD-only and “balanced” (CBD + THC) offerings available in Canada. Launched on the heels of incredible growth in sales from the Company’s THC-infused beverages, released earlier this year, Canopy Growth is uniquely positioned to win market share in the CBD beverage space.

“We are proud to debut our first CBD-infused beverage brand in Canada, where we already lead the cannabis-infused beverage category, at a price point that delivers both quality and value to consumers,” said David Klein, CEO, Canopy Growth.  “We created Quatreau as an alternative to sugary, caffeinated beverages or even alcohol. With both CBD-only and “balanced” (CBD + THC) offerings in four natural  flavours, Quatreau meets the needs of discerning cannabis consumers.”

Canopy Growth plans to continue developing category leading brands that are driven by consumer insights, product-focused, with industry leading scientific formulation. Building on the successful launch and strong sales of THC-infused cannabis beverage brands Tweed, Houseplant and Deep Space, Canopy is poised to continue leading the cannabis space with the launch of Quatreau CBD-infused sparkling water, a consistent CBD product in a beverage format that is familiar to consumers.

Quatreau’s naturally flavoured Canadian product line includes four offerings named:

  • Quatreau Cucumber + Mint (contains 20 mg of CBD and < 1 mg of THC)
  • Quatreau Passion Fruit + Guava (contains 20 mg of CBD and < 1 mg of THC)
  • Quatreau Ginger + Lime (contains 2 mg of CBD and 2 mg of THC)
  • Quatreau Blueberry + Açai (contains 2 mg of CBD and 2 mg of THC)

For more information, visit quatreauwater.com

Montana Department Of Agriculture Releases Hemp Marketplace

Montana hemp buyers and sellers can connect through new Hemp Marketplace

MONTANA: The Montana Department of Agriculture (MDA) announced today that the Hemp Marketplace is now available to buyers and sellers of hemp and hemp derivatives. The online portal can be accessed by visiting the department’s website.

“With hemp being a relatively new crop grown in Montana, the department recognizes that these markets are still developing,” said MDA Director Ben Thomas. “The Hemp Marketplace was developed to help facilitate connections between buyers and sellers. I’m looking forward to seeing how the marketplace will continue to advance the industry.”

The Hemp Marketplace concept originated from the same idea as the department’s Hay Hotline, only instead of hay and pasture, the online tool connects buyers and sellers of hemp and hemp derivatives. Because hemp is a regulated crop, only growers that are licensed through the Montana State Hemp Program are permitted to list hemp for sale and all listings must be comply with the 0.3% threshold for THC.

Users can enter new listings or view existing listings free of charge by visiting MDA’s main website at agr.mt.gov, then selecting “Hemp Marketplace” from the “Topics” dropdown. MDA staff are also available to help assist with listings by phone at (406) 444-2402, by email at agr@mt.gov, and by fax at (406) 444-9493.